Orphazyme A/S (0CUM.L)
| Previous close | 1.9996 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -17.9400 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Orphazyme reports financial results in Interim Report First Half 2022
Company announcementOrphazyme A/SNo. 36/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, September 26, 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”) today announces its Interim Report First Half 2021 for the period January 1 – June 30, 2022. Anders Vadsholt, Chief Executive Officer and Chief Financial Officer said, “During the first half of 2022, we executed the sale of substantially all of Orphazyme’s assets, including the continuing development of arimoclomol, to
- Globe Newswire
Adjusted financial outlook for 2022
Orphazyme A/SCompany announcement No. 35/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, September 25, 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”) has decided to adjust its outlook for 2022, as published on June 7, 2022. The change is driven by the separation of activities into continuing and discontinued operations. The discontinued activities are related to the sale of assets to KemPharm A/S. The continuing business activities are the limited ongoing operationa
- Globe Newswire
Updated financial calendar for 2022
Company announcement Orphazyme A/SNo. 34/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, September 19, 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”) announces an update to the Company’s financial calendar in regard to the publication of the Company’s Interim Report First Half 2022. The Interim Report First Half 2022 will be published on September 26, 2022, previously September 20, 2022. Additional time is required to conclude the presentation of the financial state
